The DOI matches its Crossref record.
A New Concept: The Use of Vanadium Complexes in the Treatment of Diabetes Mellitus
Abstract
In the 21st century, patients suffering from diabetes mellitus (DM), a lifestyle‐related disease, will increase more than in the 20th century. DM is threatening because of the development of many severe secondary complications, including atherosclerosis, microangiopathy, renal dysfunction and failure, cardiac abnormalities, diabetic retinopathy, and ocular disorders. Generally, DM is classified as either insulin‐dependent type 1 or noninsulin‐dependent type 2 DM. Type 1 DM is treated only by daily insulin injections; type 2 DM is treated by several types of synthetic therapeutic substances together with a controlled diet and physical exercise. Even with these measures, the daily necessity for several insulin injections can be painful both physically and mentally, whereas the synthetic therapeutic substances used over the long term often have side effects. For those reasons, the creation and development of a new class of pharmaceuticals for treatment of DM in the 21st century would be extremely desirable. In the last half of the 20th century, investigations of the relationships among diseases and micronutrients, such as iron, copper, zinc, and selenium, have been numerous. Research into the development of metallopharmaceuticals involving the platinum‐containing anticancer drug, cisplatin, and the gold‐containing rheumatoid arthritis drug, auranofin, has also been widespread. Such important findings prompted us to develop therapeutic reagents based on a new concept to replace either insulin injections or the use of synthetic drugs. After many trials, we noticed that vanadium might be very useful in the treatment of DM. Before the discovery of insulin by Banting and Best in 1921 and its clinical trial for treating DM, the findings in 1899, in which orally administered sodium vanadate (NaVO 3) was reported to improve human DM, gave us the idea to use vanadium to treat DM. However, it has taken a long time to obtain a scientific explanation as to why the metal ion exhibits insulin‐mimetic or blood‐glucose lowering effects in in vitro and in vivo experiments. After investigations from many perspectives involving biochemistry and bioinorganic chemistry, vanadyl sulfate (VOSO 4) and its complexes with several types of ligands have been proposed as useful for treating DM in experimental diabetic animals. On the basis of a mechanistic study, this article reports on recent progress regarding the development of antidiabetic vanadyl complexes, emphasizing that the vanadyl ion and its complexes are effective not only in treating or relieving both types of DM but also in preventing the onset of DM. © 2002 The Japan Chemical Journal Forum and Wiley Periodicals, Inc., Chem Rec 2: 237–248, 2002: Published online in Wiley InterScience (www.interscience.wiley.com) DOI 10.1002/tcr.10029
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 58
- Lyonnet B., 1899, Presse Med, 1, 191
- 10.1021/bk-1998-0711 · DOI · Paper page
- 10.1021/cr980427c · DOI · Paper page
- 10.2337/diab.46.11.1786 · DOI · Paper page
- 10.1023/A:1017961029492 · DOI
- 10.1007/BF00627693 · doi:10.1007/bf00627693
- 10.1152/ajpendo.1998.274.6.E984 · DOI
- 10.1248/cpb.49.652 · DOI
- 10.1007/s007750100266 · DOI
- 10.1007/BF00400407 · DOI
- 10.1016/S0955-2863(01)00190-5 · DOI
- 10.1007/s001250100479 · doi:10.1007/s001250100479
- Lippard S.J., 1994, Principles of Bioinorganic Chemistry, 16
- 10.1248/bpb.18.719 · DOI · Paper page
- 10.1677/joe.0.1260451 · DOI · Paper page
- 10.3164/jcbn.8.193 · doi:10.3164/jcbn.8.193
- 10.1016/S0020-1693(00)91885-1 · doi:10.1016/s0020-1693(00)91885-1
- 10.1021/jm00033a002 · doi:10.1021/jm00033a002
- 10.1016/S0020-1693(98)00309-0 · doi:10.1016/s0020-1693(98)00309-0
- 10.1246/cl.1999.913 · doi:10.1246/cl.1999.913
- 10.1016/S0162-0134(00)00045-3 · DOI
- 10.1016/S0162-0134(01)00192-1 · doi:10.1016/s0162-0134(01)00192-1
- 10.1021/jm00086a020 · doi:10.1021/jm00086a020
- 10.1139/y93-041 · doi:10.1139/y93-041
- 10.1139/y93-042 · doi:10.1139/y93-042
- 10.1021/ja991567m · doi:10.1021/ja991567m
- 10.1007/s007750000180 · doi:10.1007/s007750000180
- 10.1246/cl.2000.866 · doi:10.1246/cl.2000.866
- Kawabe K., 1998, Chem Lett, 9
- 10.1021/ja984225 · doi:10.1021/ja984225
- 10.1246/cl.1998.1155 · doi:10.1246/cl.1998.1155
- 10.1006/bbrc.1995.2398 · DOI · Paper page
- Sakurai H., 2000, Inorg React Mech, 2, 69
- 10.3164/jcbn.23.113 · doi:10.3164/jcbn.23.113
- 10.1211/0022357991772213 · DOI
- 10.1007/s007750000182 · doi:10.1007/s007750000182
- 10.1248/cpb.47.1668 · doi:10.1248/cpb.47.1668
- 10.1016/S0162-0134(01)00342-7 · doi:10.1016/s0162-0134(01)00342-7
- 10.1016/S0162-0134(99)00215-9 · doi:10.1016/s0162-0134(99)00215-9
- 10.1016/S0162-0134(00)00041-6 · doi:10.1016/s0162-0134(00)00041-6
- 10.1016/0014-5793(95)92711-I · doi:10.1016/0014-5793(95)92711-i
- 10.1016/S0162-0134(99)00204-4 · doi:10.1016/s0162-0134(99)00204-4
- 10.1211/0022357011776531 · DOI
- 10.1210/jc.86.3.1410 · DOI
- 10.1016/S0021-9258(20)82192-9 · DOI · Paper page
- Bernier M., 1988, J Biol Chem, 263, 13626, 10.1016/S0021-9258(18)68288-2 · DOI
- 10.1016/S0006-291X(88)80452-2 · DOI
- Ueno A., 1987, Biochem Biophys Res Commun, 144
- 10.1042/bj2560903 · DOI
- Okumura N., 1992, J Biochem, 112
- 10.1007/BF00229769 · doi:10.1007/bf00229769
- Boyd D.W., 1984, Adv Inorg Biochem, 6, 311
- 10.1016/0006-2952(84)90498-2 · doi:10.1016/0006-2952(84)90498-2
- Ramasarma T., 1981, Curr Top Cell Regul, 20, 249
- Marzban L., 2001, Mol Cell Biochem, 223
- Mohammad A., 2001, Mol Cell Biochem, 223
- Nriagu J.O., 1998, Vanadium in the Environment. Part 1: Chemistry and Biochemistry; Part 2: Health Effects, 297
- 10.1006/bbrc.1996.1385 · doi:10.1006/bbrc.1996.1385
Cited by
ISSN exercise & sports nutrition review update: research & recommendations
Kerksick, C. M., Wilborn, C. D., Roberts, M. D., Smith-Ryan, A., Kleiner, S. M., Jäger, R., Collins, R., Cooke, M., Davis, J. N., Galvan, E., et al. (2018) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-018-0242-y · Cited by 945
Vanadium compounds in medicine
Pessoa, J. C., Etcheverry, S., & Gambino, D. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.12.002 · Cited by 561
Westman, E. C., Yancy, W. S., Mavropoulos, J. C., Marquart, M., & McDuffie, J. R. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-36 · Cited by 475
“Both groups received the same nutritional supplements known to have a mild lowering effect on blood glucose levels (vanadyl sulfate 200 mcg/day, chromium dicotinate glycinate 600 mcg/day, alpha-lipoic acid 200 mg/day) [17,18].”
BackgroundThe pharmacology of the insulinomimetic effect of zinc complexes
Sakurai, H., & Adachi, Y. (2005) · BioMetals · doi:10.1007/s10534-005-3688-8 · Cited by 76
Self-citationAntidiabetic Activity of Zn(II) Complexes with a Derivative of l-Glutamine
Matsumoto, K., Yamamoto, S., Yoshikawa, Y., Doe, M., Kojima, Y., Sakurai, H., Hashimoto, H., & Kajiwara, N. M. (2005) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.78.1077 · Cited by 17
Self-citation
Metadata
- Authors
- Sakurai, H.
- Venue
- The Chemical Record
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 2
- Issue
- 4
- Pages
- 237-248
- ISSN
- 1527-8999 (ISSN-L)
- 1528-0691
- OpenAlex
- W1989381085
- Cited by
- 164
- References
- 0
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.